menu
    • menu
    [{"orgOrder":0,"company":"Pherecydes Pharma","sponsor":"Erytech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"Anti-Staphylococcus Aureus Bacteriophage","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pherecydes Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pherecydes Pharma \/ Erytech Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Pherecydes Pharma \/ Erytech Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Pherecydes Pharma

    Menu

    Pherecydes Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pherecydes Pharma

                            France arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Pherecydes Pharma

                            France arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anti-Staphylococcus Aureus Bacteriophage

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Erytech Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Thera...

                            Details : Strategic combination will accelerate development of extended phage therapies for antimicrobial resistance including Anti-Staphylococcus aureus Bacteriophages, in particular via the phase II PhagoDAIR study conducted by PHERECYDES.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 15, 2023

                            Lead Product(s) : Anti-Staphylococcus Aureus Bacteriophage

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Erytech Pharma

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth